Reply to Ward and Colleagues' Comment on "Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors"
Drug Saf
.
2018 Nov;41(11):1101.
doi: 10.1007/s40264-018-0701-z.
Authors
Rebecca N Jerome
1
,
Jill M Pulley
2
,
Dan M Roden
3
,
Jana K Shirey-Rice
2
,
Lisa A Bastarache
4
,
Gordon Bernard
2
3
,
Leeland Ekstrom
2
5
,
William J Lancaster
4
,
Joshua C Denny
4
Affiliations
1
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
[email protected]
.
2
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
3
Office of Research, Vanderbilt University Medical Center, Nashville, TN, USA.
4
Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA.
5
Nashville Biosciences, Nashville, TN, USA.
PMID:
30066313
DOI:
10.1007/s40264-018-0701-z
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
Comment
MeSH terms
Humans
Proprotein Convertase 9*
Substances
PCSK9 protein, human
Proprotein Convertase 9
Grants and funding
UL1 TR002243/TR/NCATS NIH HHS/United States